CIK 0001590560
- Large accelerated filer
uniQure N.V.
Sign in to watch- Ticker
- QURE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +1 339-970-7000
- Business address
- PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP
- Former names
- uniQure B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $192,950
- in 1 filing, $193K under 10b5-1 plans
Net −$192,950. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-08 | Abi-Saab Walid Chief Medical Officer | Exercise or conversion 10b5-1 | +25,000 | $5.59 | $140K | 214,669 |
| 2026-05-08 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −25,000 | $25.10 | $628K | 189,669 |
| 2026-05-08 | Abi-Saab Walid Chief Medical Officer | Sale 10b5-1 | −20,000 | $25.00 | $500K | 169,669 |
| 2026-05-08 | Abi-Saab Walid Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −25,000 | 60,500 | ||
| 2026-03-04 | O'Keefe Kylie Chief Customer & Strat Officer | Grant or award | +19,800 | 124,800 | ||
| 2026-03-04 | O'Keefe Kylie Chief Customer & Strat Officer | Grant or award · Stock Option (Right to Buy) | +31,900 | 31,900 | ||
| 2026-03-04 | Kapusta Matthew C CEO, Managing Director | Grant or award | +70,600 | 675,239 | ||
| 2026-03-04 | Kapusta Matthew C CEO, Managing Director | Sale | −14,581 | $9.06 | $132K | 660,658 |
| 2026-03-04 | Kapusta Matthew C CEO, Managing Director | Grant or award · Stock Option (Right to Buy) | +113,800 | 113,800 | ||
| 2026-03-04 | Abi-Saab Walid Chief Medical Officer | Grant or award | +41,700 | 190,477 | ||
| 2026-03-04 | Abi-Saab Walid Chief Medical Officer | Sale | −808 | $9.06 | $7K | 189,669 |
| 2026-03-04 | Abi-Saab Walid Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +67,200 | 67,200 | ||
| 2026-03-04 | Potts Jeannette Chief Legal Officer | Grant or award | +35,400 | 141,895 | ||
| 2026-03-04 | Potts Jeannette Chief Legal Officer | Sale | −3,412 | $9.06 | $31K | 138,483 |
| 2026-03-04 | Potts Jeannette Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +57,200 | 57,200 | ||
| 2026-03-04 | KLEMT CHRISTIAN Chief Financial Officer | Grant or award | +39,600 | 238,581 | ||
| 2026-03-04 | KLEMT CHRISTIAN Chief Financial Officer | Sale | −12,000 | $9.06 | $109K | 226,581 |
| 2026-03-04 | KLEMT CHRISTIAN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +63,900 | 63,900 | ||
| 2026-03-02 | Kapusta Matthew C CEO, Managing Director | Sale | −34,437 | $9.95 | $343K | 604,639 |
| 2026-03-02 | KLEMT CHRISTIAN Chief Financial Officer | Sale | −12,532 | $9.95 | $125K | 198,981 |
Page 5 of 13 · 251 trades